Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Non-Current Debt: 2021-2025

Historic Non-Current Debt for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $171.9 million.

  • Legend Biotech's Non-Current Debt fell 42.04% to $171.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.9 million, marking a year-over-year decrease of 42.04%. This contributed to the annual value of $301.2 million for FY2024, which is 7.06% up from last year.
  • Latest data reveals that Legend Biotech reported Non-Current Debt of $2,000.0 billion as of Q3 2025, which was down 0.00% from $2,000.0 billion recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Non-Current Debt ranged from a high of $310.3 million in Q2 2025 and a low of $2.5 million during Q2 2022.
  • For the 3-year period, Legend Biotech's Non-Current Debt averaged around $2,000.0 billion, with its median value being $2,000.0 billion (2025).
  • Per our database at Business Quant, Legend Biotech's Non-Current Debt plummeted by 91.99% in 2022 and then skyrocketed by 10,660.00% in 2023.
  • Quarterly analysis of 4 years shows Legend Biotech's Non-Current Debt stood at $2,000.0 billion in 2022, then remained steady at $2,000.0 billion in 2023, then remained steady at $2,000.0 billion in 2024, then remained steady at $2,000.0 billion in 2025.
  • Its last three reported values are $171.9 million in Q3 2025, $310.3 million for Q2 2025, and $305.7 million during Q1 2025.